Other languages Cybin Inc. OTC Markets

Equities

CLXP.F

CA23256X1006

End-of-day quote OTC Markets Other stock markets 23:00:00 31/08/2021 BST			5-day change	1st Jan Change
2.63 ^CAD	-6.07%		+17.41%	+76.51%

04-17	Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	MT
04-16	Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Softer Friday Afternoon	03-15
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder	03-15
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder	03-15
Cybin berichtet über ein positives Treffen mit der FDA zum Ende der Phase 2 für CYB003 bei schweren depressiven Störungen und über die Planung eines Programms der Phase 3	03-14
Cybin annonce une réunion positive avec la FDA à la fin de la phase 2 pour le CYB003 dans le trouble dépressif majeur et la conception du programme de phase 3	03-14
Cybin Reaches Alignment With FDA on Late-Stage Design For Major Depressive Disorder Trial	03-14
Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design	03-14
Cybin reçoit la désignation de thérapie innovante de la FDA pour sa molécule psychédélique CYB003 et annonce des données de durabilité positives à quatre mois pour le traitement du trouble dépressif majeur	03-13
Annonce d’un placement privé sursouscrit de 150 millions USD	03-13
Cybin erhält von der FDA den Status eines Therapiedurchbruchs für sein neuartiges psychedelisches Molekül CYB003 und gibt positive Daten zur viermonatigen Dauerhaftigkeit bei schwerer depressiver Störung bekannt	03-13
Sector Update: Health Care Stocks Ease Wednesday Afternoon	03-13
Ankündigung einer überzeichneten Privatplatzierung von 150 Millionen US-Dollar	03-13
Cybin Says Depression Drug Granted Breakthrough Designation by FDA; Raises $150 Million in Private Placement; Shares Jump	03-13
Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder	03-13
Cybin Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14
Cybin Gets FDA Clearance for Generalized Anxiety Disorder Study	01-23
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder	01-23
Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028	01-08
Cybin Inc. Announces Recent Positive Phase 2 CYB003 Topline Results in MDD and Outlines Key Upcoming Milestones Across its Clinical Development Programs	01-04
Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting	12-06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cybin Inc. OTC Markets

Equities

CLXP.F

CA23256X1006

Other languages

Filters